AKAMIS BIO LIMITED

• ⚠

  Material uncertainty over going concern

  These circumstances represent a material uncertainty which may cast significant doubt on the group's and company's ability to continue as a going concern. Therefore, the group and company may be unable to realise their assets and discharge their liabilities in the normal course of business.

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. AKAMIS BIO LIMITED 2023-01-03 → present
2. PSIOXUS THERAPEUTICS LIMITED 2011-01-05 → 2023-01-03
3. MYOTEC THERAPEUTICS LTD. 2006-11-17 → 2011-01-05

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“These circumstances represent a material uncertainty which may cast significant doubt on the group's and company's ability to continue as a going concern. Therefore, the group and company may be unable to realise their assets and discharge their liabilities in the normal course of business.”

Group structure

1. AKAMIS BIO LIMITED · parent
   1. Hybrid Biosystems Limited 100% · England · was dormant
   2. AkaBio US LegacyCo, Inc. 100% · USA · research and development

Significant events

• “In February 2025, the Group announced the strategic decision to move its UK operations and related activities to the United States.”
• “On 9 December 2024, the Group entered into a license agreement with a new partner, to grant them the exclusive license to develop, manufacture and commercialise the viral vector developed from the T-Sign Platform technology.”
• “On 17 October 2024 the group raised additional funding through a Series A Prime Equity raise.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

14

last 12 months

Capital events

7

last 24 months

Officers appointed

0

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +1,177.3%

  £1,041,795 → £13,306,610

• Cash

  -22.9%

  £17,349,455 → £13,378,519

• Net assets

  +10,428.5%

  £101,377 → £10,673,480

• Employees

  -58.3%

  72 → 30

• Operating profit

  +91.4%

  -£23,766,025 → -£2,039,420

• Profit before tax

  +81.8%

  -£9,097,934 → -£1,652,478

• Wages

  -42.9%

  £6,764,483 → £3,863,748

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers